4 news items
Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Extension In Time To Intracranial Progression For Patients With Brain Metastases From Non-Small Cell Lung Cancer
NVCR
ZLAB
27 Mar 24
and median usage was 67%. Consistent with previous studies, TTFields therapy was well-tolerated with sustained quality of life and neurocognitive
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
NVCR
ZLAB
27 Mar 24
was 67%. Consistent with previous studies, TTFields therapy was well-tolerated with sustained quality of life and neurocognitive function. Baseline
Stock Disconnect Triggers Investor Exodus From CStone Pharma
ZLAB
14 Mar 24
by waves of selling and ended last week down 39.2%.
With the Hong Kong stock market in a sustained slump, unprofitable biomedical companies
Qiming Venture Partners Becomes a UN PRI Signatory
BILI
SDGR
ZH
25 Feb 24
(PRI). By signing the PRI, Qiming has joined an international network of over 5,000 signatories that share a mission to shape a global sustainable
- Prev
- 1
- Next